Pancreatic pseudocyst with stent placement in the background of narcotic use: a case report

Stephen Offord*1, Bora Gumustop2 and Arthur Shepard3

Address: 1Department of Family Practice, Saratoga Hospital, 211 Church Street, Saratoga Springs, NY 12866, USA, 2Gastroenterologist, Albany Gastroenterology Consultants, PC, 1375 Washington Avenue, Suite 101, Albany, NY 12206, USA and 3Medical Imaging, Information Systems Supervisor, Saratoga Hospital, 211 Church Street, Saratoga Springs, NY 12866, USA

Email: Stephen Offord* - srofford@aol.com; Bora Gumustop - office@albanyGI.com; Arthur Shepard - ashepard@saratogacare.org

* Corresponding author

Abstract

A 49 year old gentleman presents with recurrent abdominal pain. The patient has a known history of chronic pancreatitis, alcoholism and narcotic addiction. Work-up, including computed tomography (CT) of the abdomen, demonstrated a 5.6 × 5.8 cm fluid collection contiguous with the pancreas. This was not seen on CT 18 months earlier. The patient's pain did not improve with bowel rest and pain control. He was transferred to another institution for endoscopic placement of a transgastric pancreatic stent. The procedure decreased the size the cyst and the patient's pain became more manageable.

Introduction

Pancreatic pseudocysts have been recognized for over 185 years [1]. Today most are alcohol related and more than half are thought to resolve spontaneously [2]. This is a case of a 49 year old gentleman who develops a pancreatic pseudocyst that had to be surgically drained. Pancreatic pseudocysts have a unique physiology that does not lend itself easily to drainage [3]. Consequently management has tended towards watchful waiting provided the cyst is stable and asymptomatic [4]. Our patient also had narcotic dependence. Some evidence suggests at least a physiologic basis for the contribution of some narcotics towards the development of a pancreatic pseudocyst [5-7].

Case presentation

History of Present Illness

The patient was a 49 year old patient who presented with abdominal pain. He had visited our emergency room 13 times in the last year and this would be his fourth admission. His abdominal pain was constant, mid-epigastric, and exacerbated with eating. Why the pain flared up this time was unclear. He did not consume any alcohol recently or change his diet. He denied chest pain, shortness of breath, melena and fever. He had not vomited but was nauseated.

Past Medical History

His only medical problem was chronic pancreatitis and its complications. His pancreatitis was initially precipitated by heavy alcohol use. In recent years he no longer drank alcohol but was addicted to lortab. We were informed that at one time he would take up to 30 or 40 pills a day of lortab purchased illegally off the street.

Past Surgical History

None
Past Social History
The patient smoked one pack per day. He no longer drank alcohol. He was disability for chronic pancreatitis. He denied drug use at this time, including non prescribed narcotics.

Past Family History
His mother passed away from coronary artery disease. As far as he knew, it did not develop when she was young.

Medications
His narcotic use varies. Presently he was taking lortab 5/500 mg, four tablets a day. He also took Viokase-8 tablets, four before meals and two before snacks.

Physical Exam
Vital signs: Afebrile. Pulse 77. Respiratory rate 18. Blood pressure 135/73. Oxygen saturation 100% on room air.

In general he seemed uncomfortable. He sat still and winced when he talked. Head exam: Normal cephalic, atraumatic. Ears and throat were normal. He had poor dentition although he still has his own teeth. Neck: I did not note lymphadenopathy or a carotid murmur. Heart: regular rate and rhythm. No murmur was noted. Lung exam: clear with good air movement. Abdomen: Tenderness with palpation in the epigastric region. There was no guarding or rebound tenderness. His abdomen was not rigid. Bowel sounds were quiet. Extremities: no edema and no clubbing of nails.

Laboratory
His amylase was elevated at 239 IU/L. White cell count was $10.4 \times 10^3/\mu L$ with 76% neutrophils. Hemoglobin was 14.6 g/dL. His metabolic panel was normal. Calcium was 8.7 mg/dL and his albumin was 3.4 g/dL. His triglycerides were 128 mg/dL. His alcohol level was 0.

Computed tomography (CT) with contrast of the abdomen and pelvis (figure 1) showed a large $5.6 \times 5.8$ cm low attenuation collection with a well-defined wall contiguous with the body of the pancreas. Mild fat stranding was also noted around the pancreatic tail.

A CT of the abdomen 18 months earlier (figure 2) demonstrated no pseudocyst or pancreatic inflammation.

Hospital course
The patient was admitted for bowel rest and pain control. Because of continued abdominal pain, several days passed and he still was unable to tolerate oral intake. Total parenteral nutrition was provided. Follow up CT scans of the abdomen on hospital days 7 and 14 showed no change.

Figure 1
CT of the abdomen showing a large $5.6 \times 5.8$ cm fluid collection contiguous with the body of the pancreas.

Finally, on hospital day 24 he was transferred to another institution for pseudocyst drainage and stent placement. He underwent transgastric endoscopic ultrasound and...

Figure 2
CT of the abdomen of the same patient 18 months earlier. No pancreatic fluid collection is seen.
fluoroscopy guided pseudocyst drainage with stent placement.

Outcome
The patient's pain improved following stent placement. Following discharge, the patient continued to have periodic admissions for flare ups of abdominal pain, but they became less frequent. Figure 3 shows a CT of the patient's abdomen seven months later. The pseudocyst measures 17 mm in size with the stent still in place. The patient was also enrolled in a methadone program to address his narcotic addiction.

About two years after this admission the patient expired. He died at his home suddenly. Autopsy reports concluded cause of death to be a drug overdose, methadone and hydrocodone. It also noted severe atherosclerosis of the coronary arteries.

Discussion
Pancreatic pseudocysts develop after acute pancreatitis 5 to 15% of the time, and more than half are thought to resolve spontaneously. Most (~65%) are alcohol related [2]. While true cysts have an epithelial lining that secretes the cystic fluid, pancreatic pseudocysts are filled with exocrine secretions from a disruption of its own ductal system. The body reacts to the hostile, digestive enzymes-amylase, lipase and others, with inflammation. A fibrous wall forms over several weeks to contain the spill and protect the surrounding tissue [2,3].

Persistence of the cyst implies an ongoing communication with the disrupted pancreatic duct [3]. The patient's chronic abdominal pain was likely due, at least in part, to the development of a pseudocyst. Pseudocysts seem more likely to persist in patients who continue to drink alcohol [2,4]. Their persistence in narcotic users is less appreciated.

Pancreatic pseudocyst management has tended towards watchful waiting [3,8,9]. The first planned operation of a pancreatic cyst was in 1822 in Prague by Carl Gussenbauer [1]. He palpated an 8.5 × 22 cm swelling in the epigastrium of a 40 year old man who recently drank 7 liters of beer. An abdominal incision was used to drain 1900 cc of grayish, black fluid. The patient improved but later developed an external pancreatic fistula. He was discharged against medical advice on post-operative day 84.

Back then, pancreatic pseudocysts were diagnosed by physical exam [1]. Consequently, cysts had to be quite large before they could be found. Even with the help of an upper GI series, introduced in 1910 [10], any cysts discovered were big, and spontaneous resolution was thought to be rare (less than 10%). As a result, most that were discovered were drained [1].

Two conservative trends followed and each was driven, in part, by advances in imaging [3]. The first trend occurred one hundred and fifty years after Gussenbauer's partial success. In 1979, Bradley and colleagues followed the natural history of pseudocysts by ultrasonography. They noted cysts less than 6 cm had a 40% spontaneous resolution rate and a very low complication rate (20%). Pseudocysts present more than 6 weeks, however, almost never resolved and had a very high complication rate (46%). Consequently there was a strong trend to observe smaller, younger pseudocysts [8]. Surgical drainage was reserved for cysts 'greater than 6 cm or present for more than 6 weeks'.

The second and latest trend followed a study using computed tomography (CT) imaging [9]. In the late 1980's, Yeo et al observed the natural history of pseudocysts by CT. The '6 cm or 6 week' paradigm began to falter. He noted for, example, 36% of pseudocysts greater than 8 cm could be managed without surgery. Later, Vitas and Sarr described 68 patients with pancreatic pseudocysts managed expectantly for as long as 116 months (mean 51 months). Serious complications were seen in 9% of this expectant group compared to 10% of patients who had elective operations in the primary treatment group [4]. Now there is no longer a cut and dried quantitative policy.
Many patients manage the pain of chronic pancreatitis with narcotics.

**Competing interests**
The authors declare that they have no competing interests.

**Authors’ contributions**
SO drafted the manuscript. BG provided insight into the discussion. AS provided technical assistance with the CT images. All authors read and approved the manuscript.

**Consent**
Written informed consent was obtained from the patient’s Health Care Agent for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

**Acknowledgements**
The authors wish to thank the patient and his family for allowing us to be a part of his care.

**References**

1. Schnellendorf T, Yan Y, Kitvaramaetha MS, Adams DB: Carl Gussen-bauer: Pioneer in Pancreatic Surgery. World J Surg 2003, 27:753-757.

2. Yeo CJ, Sarr MG: Cystic and Pseudocystic Diseases of the Pancreas. Curr Probl Surg 1994, 31(3):165-243.

3. Cooperman AM: An Overview of pancreatic Pseudocysts. The Emperor’s new Clothes Revisited. Surg Clin North Am 2001, 81(2):391-397.

4. Vitas GJ, Sarr MG: Selected Management of Pancreatic Pseu-
docysts: Operative Versus Expectant Management. Surgery 1992, 111:123-130.

5. Helm JF, Venu RP, Geenen JE, Hogan WJ, Dodds WJ, Touli J, Arndorfer RC: Effects of Morphine on the Human Sphincter of Oddi. Gut 1988, 29:1402-1407.

6. Wu SD, Zhang ZH, Jin JZ, Kong J, Wang W, Zhang Q, Li DY, Wang MF: Effects of Narcotic Analgesic Drugs on Human Oddi’s Sphincter Motility. World J Gastroenterol 2004, 10(19):2901-2904.

7. Gullo L, Priori P, Costa PL, Garcea D, Baldoni F,Mattioni G, Labo G: Effects of Morphine on Human Pancreatic Secretion: Studies on Pure Pancreatic Juice. Gut 1982, 23:739-743.

8. Bradley EL, Clements JL, Gonzalez AC: The Natural History of Pancreatic Pseudocysts: A Unified Concept of Management. Am J Surg 1979, 137:135-41.

9. Yeo CJ, Bastidas JA, Lynch-Nynch A, Fishman EK, Zinner MJ, Cam-
eron JL: The Natural History of Pancreatic Pseudocysts Doc-
umented by Computed Tomography. Surg Gynecol Obstet 1990, 170(5):411-417.

10. Chen JR: Reassessment of Barium Radiographic Examination in Diagnosing Gastrointestinal Diseases. World J Gastroenterol 1999, 5(5):383-87.

11. Pichumoni CS, Agarwal N: Pancreatic Pseudocysts. When and How Should drainage Be performed? Gastroenterol Clin of North Am 1999, 28(3):615-638.

12. Dooley Cornelius P, Saad Carlos, Valenzuela Jorge E: Studies of the Role of Opioids in Control of Human Pancreatic Secretion. Dig Dis Sci 1998, 33(5):598-604.

13. Wilder-Smith CH, Hill LS, Osler W, O'Keefe S: Effect of Tramadol and Morphine on Pain and Gastrointestinal Motor Function in Patients with Chronic Pancreatitis. Dig Dis Sci 1999, 44(6):1107-1116.